PharmaEssentia Corporation (LUX:261280558)

Luxembourg flag Luxembourg · Delayed Price · Currency is EUR · Price in USD
16.60
+0.10 (0.61%)
At close: Dec 3, 2025
-6.74%
Market Cap 5.21B
Revenue (ttm) 386.25M
Net Income (ttm) 134.33M
Shares Out n/a
EPS (ttm) 0.36
PE Ratio 38.79
Forward PE 27.16
Dividend 0.02 (0.11%)
Ex-Dividend Date Aug 11, 2025
Volume n/a
Average Volume n/a
Open n/a
Previous Close 16.50
Day's Range n/a
52-Week Range 13.58 - 23.57
Beta n/a
RSI 56.01
Earnings Date Nov 13, 2025

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 131
Stock Exchange Luxembourg Stock Exchange
Ticker Symbol 261280558
Full Company Profile

Financial Performance

Financial numbers in TWD Financial Statements

News

There is no news available yet.